

## Elenco Poster

ID N. pgm Title

## Antiretroviral therapy

- 269 P 1** Liver enzyme elevations according to the first line cART regimen: real life data from the ICONA cohort  
*L. Taramasso<sup>1</sup>, P. Lorenzini<sup>2</sup>, A. Di Biagio<sup>3</sup>, M. Lichtner<sup>4</sup>, G. Marchetti<sup>5</sup>, R. Rossotti<sup>6</sup>, G. Lapadula<sup>7</sup>, D. Minisci<sup>8</sup>, F. Vichi<sup>9</sup>, A. Antinori<sup>2</sup>, S. Bonora<sup>10</sup>, A. d'Arminio Monforte<sup>5</sup> for ICONA Foundation Study Group*
- 94 P 2** Therapy with darunavir/cobicistat impacts on total cholesterol and glomerular filtration rate  
*L. Taramasso<sup>1</sup>, E. Ricci<sup>2</sup>, A. Cascio<sup>3</sup>, B. Menzaghi<sup>4</sup>, L. Valsecchi<sup>5</sup>, N. Squillace<sup>6</sup>, G.V. De Socio<sup>7</sup>, C. Dentone<sup>8</sup>, P. Maggi<sup>9</sup>, C. Martinelli<sup>10</sup>, L. Calza<sup>11</sup>, M. Garau<sup>12</sup>, P. Bonfanti<sup>13</sup>, A. Di Biagio<sup>14</sup>, on Behalf of CISAI study group*
- 127 P 3** Copy-years viremia in HIV-1 patients treated for a long time: risk of virological failure and association with inflammation markers  
*F. Falasca<sup>1</sup>, L. Mazzuti<sup>1</sup>, E. Cinquina<sup>1</sup>, G. d'Etto<sup>2</sup>, I. Mezzaroma<sup>2</sup>, M. Falciano<sup>3</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup>*
- 101 P 4** Metabolic and renal impact of switching from boosted PIs to INI-containing regimens in a monocentric cohort of drug-experienced HIV-positive subjects  
*A. Giacomelli, A. Ranzani, E. Gervasi, L. Oreni, T. Formenti, V. Di Cristo, S. De Rose, M. Franzetti, A.L. Ridolfo, M. Galli, S. Rusconi*
- 281 P 5** Changes in lipids profile and eGFR after switching from darunavir/ritonavir (DRV/r) to darunavir/cobicistat (DRV/c)- based dual therapy: a multicenter analysis  
*A. Vergori<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Giannetti<sup>1</sup>, S. Di Giambenedetto<sup>2</sup>, R. Bellagamba<sup>1</sup>, G. Sterrantino<sup>3</sup>, E. Schiaroli<sup>4</sup>, D. Francisci<sup>5</sup>, S. Cicalini<sup>1</sup>, A. Latini<sup>6</sup>, I. Mezzaroma<sup>7</sup>, M. Lichtner<sup>8</sup>, F. Di Sora<sup>9</sup>, G. D'Etto<sup>7</sup>, G. Maffongelli<sup>10</sup>, A. Antinori<sup>1</sup>, M. Zaccarelli<sup>1</sup>*
- 302 P 6** Reasons for choosing darunavir/ritonavir 600/100 mg twice daily vs. 800/100 mg once daily in treatment-naïve patients: 10 years data from the ICONA cohort  
*A. Tavelli<sup>1</sup>, M. Palma<sup>2</sup>, S. Lo Caputo<sup>3</sup>, G. Madeddu<sup>4</sup>, P. Bonfanti<sup>5</sup>, B. Menzaghi<sup>6</sup>, S. Nozza<sup>7</sup>, A. Antinori<sup>8</sup>, R. Termini<sup>2</sup>, A. d'Arminio Monforte<sup>9</sup>*
- 160 P 7** Dolutegravir plus rilpivirine versus dolutegravir plus lamivudine: a comparison between two dolutegravir-based 2-drug regimens from a multicenter cohort of treatment-experienced HIV-1 infected patients  
*A. Ciccullo<sup>1</sup>, G. Balducci<sup>1</sup>, A. Capetti<sup>2</sup>, S. Rusconi<sup>3</sup>, G. Sterrantino<sup>4</sup>, L. Celani<sup>5</sup>, S. Modica<sup>6</sup>, A. Latini<sup>7</sup>, A. Dusina<sup>1</sup>, M.V. Cossu<sup>2</sup>, S. Restelli<sup>2</sup>, A. De Luca<sup>6</sup>, S. Di Giambenedetto<sup>1</sup>*
- 213 P 8** Efficacy and safety of 2-drug combination antiretroviral therapy in clinical practice: results from a single center study  
*B. Rossetti<sup>1</sup>, G. Marri<sup>1</sup>, A. Gonnelli<sup>1</sup>, L. Toscano<sup>1</sup>, D. Marri<sup>1</sup>, P. Galluzzi<sup>1</sup>, F. Pippi<sup>1</sup>, N. Carnicelli<sup>1</sup>, C. Malcontenti<sup>1</sup>, C. Puttini<sup>1</sup>, R. Gagliardini<sup>2</sup>, F. Montagnani<sup>1,2</sup>, G. Zanelli<sup>1,2</sup>, M. Zazzi<sup>2</sup>, A. De Luca<sup>1,2</sup>*
- 289 P 9** Lack of excess concentration-related side effects in patients on dolutegravir plus atazanavir dual therapy compared to other dual regimens  
*A.F. Capetti<sup>1</sup>, C. Atzori<sup>1</sup>, M.V. Cossu<sup>1</sup>, I. Gallazzi<sup>1</sup>, M. Piscaglia<sup>1</sup>, P. Meraviglia<sup>1</sup>, D. Cattaneo<sup>2</sup>, G. Rizzardini<sup>1</sup>*
- 111 P 10** Characteristics and outcomes of naïve HIV-patients treated with Single Tablet Regimens. A single center experience  
*M. De Masi, V. Malagnino, G. Maffongelli, L. Campogiani, T. Mulas, L. Coppola, M. Compagno, A. Gentile, P. Vitale, N. Cesta, L. Sarmati, M. Andreoni*
- 132 P 11** Retrospective analysis on determinant factors of efficacy and safety of switch therapies to darunavir boosted with cobicistat (DRV/c) in different regimens  
*A. Vergori<sup>1</sup>, P. Lorenzini<sup>1</sup>, A. Giannetti<sup>1</sup>, A. Antinori<sup>1</sup>, M. Palma<sup>2</sup>, R. Termini<sup>2</sup>, M. Zaccarelli<sup>1</sup>*
- 158 P 12** Evaluation of factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen  
*D. Armenia<sup>1</sup>, C. Gori<sup>2</sup>, A. Bertoli<sup>1</sup>, V. Borghi<sup>3</sup>, M. Zaccarelli<sup>2</sup>, A. Di Biagio<sup>4</sup>, B. Bruzzone<sup>4</sup>, L. Fabeni<sup>1</sup>, W. Gennari<sup>3</sup>, D. Pizzi<sup>2</sup>, A. Giannetti<sup>2</sup>, A. Vergori<sup>2</sup>, I. Mastroianni<sup>2</sup>, A. Latini<sup>5</sup>, M. Colafigli<sup>5</sup>, C. Cerva<sup>6</sup>, R. Marocco<sup>7</sup>, M. Andreoni<sup>6</sup>, C. Mussini<sup>3</sup>, A. Antinori<sup>2</sup>, F. Ceccherini-Silberstein<sup>1</sup>, C.F. Perno<sup>2,8</sup>, M.M. Santoro<sup>1</sup>*
- 253 P 13** Dolutegravir-based dual therapy durability in clinical practice: results from the SCOLTA cohort  
*G. Madeddu<sup>1</sup>, E. Ricci<sup>2</sup>, R. Gulminetti<sup>3</sup>, G. Orofino<sup>4</sup>, A. Di Biagio<sup>5</sup>, G. VL De Socio<sup>6</sup>, M.S. Mameli<sup>1</sup>, N. Squillace<sup>7</sup>, B.M. Celesia<sup>8</sup>, B. Menzaghi<sup>9</sup>, C. Martinelli<sup>10</sup>, S. Rusconi<sup>11</sup>, C. Bellacosa<sup>12</sup>, F. Vichi<sup>13</sup>, S. Passerini<sup>14</sup>, L. Valsecchi<sup>15</sup>, L. Calza<sup>16</sup>, C. Dentone<sup>17</sup>, G. Angioni<sup>18</sup>, K. Falasca<sup>19</sup>, G.F. Pellicano<sup>20</sup>, P. Bonfanti<sup>21</sup>, C.I.S.A.I. Group, Italy*
- 52 P 14** The use of STR drugs in the management of HIV+ patients: analysis and comparison of the years 2016 and 2017  
*F. Ferrara, M. Rizzica, A. Ascani, G. Zaccaro, B. Moreno, L. Chiroso, M. Carli, S. Murachelli, A. Antinori*
- 133 P 15** Switch to Dolutegravir-based regimen in the setting of virologic suppression: study of virological and biological parameters  
*D. Di Carlo<sup>1</sup>, I. Mezzaroma<sup>2</sup>, G. d'Etto<sup>3</sup>, C. Fimiani<sup>2</sup>, M. Calabretto<sup>1</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup>*
- 264 P 16** Effect of simplification regimens on blood HIV-DNA reservoir compared to triple ART in patients with suppressed HIV-RNA  
*C. Orlandi<sup>1</sup>, B. Canovari<sup>2</sup>, Z. Pasquini<sup>2,3</sup>, F. Barchiesi<sup>2,3</sup>, M. Magnani<sup>1</sup>, A. Casabianca<sup>1</sup>*

## Elenco Poster

ID	N. pgm	Title
59	P 17	Can the new ART regimens influence adherence to guidelines in the clinical practice? Data from 2016-17 at S. Maria Annunziata Hospital, Florence, Tuscany <i>F.M. Fusco<sup>1</sup>, F. Vichi<sup>1</sup>, L. Rabatti<sup>2</sup>, M.C. Burla<sup>3</sup>, M. Prato<sup>1</sup>, P. Blanc<sup>1</sup></i>
144	P 18	Abacavir/Lamivudine/Dolutegravir (Triumeq) associated to liver toxicity in antiretroviral treatment-naive patient with HIV infection <i>S. Martini, G. Di Caprio, L. Onorato, A. Cascone, N. Coppola</i>
164	P 19	Protease Inhibitor-based dual regimens in real life <i>O. Bargiacchi<sup>1</sup>, C. Bolla<sup>2</sup>, G. Orofino<sup>3</sup>, A. Parisini<sup>2</sup>, M. Farenga<sup>3</sup>, A. Rossati<sup>1</sup></i>
210	P 20	Safety, efficacy and costs analysis of treatment simplification options in HIV-1 patients: real-world data analysis at Infectious Diseases Unit of University Hospital of Salerno <i>S. Madonia<sup>1</sup>, N. Boffa<sup>1</sup>, F.S. Mennini<sup>2</sup>, P. Sciattella<sup>2</sup></i>

## Bacterial and fungal infections in immunocompromised host

86	P 21	Are Antifungal Stewardship Programs in Immunocompromised patients needed? An Italian teaching hospital experience <i>S. Lardo, D. Faliero, A. De Luca, L. Pavan</i>
93	P 22	Antimicrobial Stewardship in Immunocompromised Hosts: a snapshot <i>D. Faliero, S. Lardo, A. De Luca, L. Pavan</i>
211	P 23	Disseminated disease caused by Mycobacterium simiae in a patient with AIDS <i>S.B. Morella, S.R. Bruno, S. Sica, S.M. Ferrara, T.A. Santantonio</i>

## Clinical HIV

187	P 24	HIV infection, but not HAART, is independently associated with increased aortic stiffness and early vascular aging <i>M. Trizzino<sup>1</sup>, G.J. Mulè<sup>1</sup>, G. Mulè<sup>2</sup>, G. Geraci<sup>2</sup>, P. Colletti<sup>1</sup>, G. Mazzola<sup>1</sup>, C. Iaria<sup>3</sup>, C. Imburgia<sup>3</sup>, C. Colomba<sup>1</sup>, S. Cottone<sup>2</sup>, A. Cascio<sup>1</sup></i>
100	P 25	Impact of integrase strand transfer inhibitor (INSTI) on body composition in a real-life setting <i>A. Bonazza<sup>1</sup>, S. Zona<sup>1</sup>, M. Menozzi<sup>1</sup>, A. Raimondi<sup>1</sup>, C. Monari<sup>2</sup>, M. Digaetano<sup>1</sup>, A. Santoro<sup>1</sup>, V. Borghi<sup>1</sup>, C. Mussini<sup>1</sup>, G. Guaraldi<sup>1</sup></i>
78	P 26	Changing face of HIV infection and ageing in two cohorts of older patients cross-sectionally observed in 2007 and in 2016 <i>F. Alessi, A. Marino, M.E. Locatelli, A. Pampaloni, D. Scuderi, M. Maresca, L. Vinci, R. Fontana del Vecchio, R. Bruno, M. Gussio, F. Palermo, B. Cacopardo, B. M. Celesia</i>
61	P 27	Development of a Frailty Index, an HIV Index and a Protective Index from a clinical HIV database <i>G. Guaraldi<sup>1</sup>, I. Franconi<sup>1</sup>, O. Theou<sup>2</sup>, L. Wallace<sup>2</sup>, A. Malagoli<sup>1</sup>, R.J.A.H. Eendebak<sup>2</sup>, C. Mussini<sup>1</sup>, K. Rockood<sup>2</sup></i>
73	P 28	Differences between infections sustained by different viral HIV subtypes in the management of antiretroviral therapy in a Roman hospital: a single experienced center <i>G. Maffongelli, M. De Masi, V. Malagnino, T. Mulas, L. Coppola, M. Compagno, L. Campogiani, A. Gentile, C. Cerva, L. Sarmati, M. Andreoni</i>
265	P 29	HIV-RNA rebound during DAA treatment: influence of treatment complexity in HIV/HCV co-infected patients <i>A. Palazzo<sup>1</sup>, L. Marinaro<sup>1</sup>, A. Barco<sup>1</sup>, S. Scabini<sup>1</sup>, N. Forni<sup>1</sup>, C. Montrucchio<sup>1</sup>, C. Alcantarini<sup>1</sup>, V. Pirriatore<sup>1</sup>, M.C. Tettoni<sup>1</sup>, L. Trentini<sup>1</sup>, J. Cusato<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. Calcagno<sup>1</sup>, A. D'Avolio<sup>1,2</sup>, G. Di Perri<sup>1</sup>, S. Bonora<sup>1</sup></i>
182	P 30	Immuno-virological response during antiretroviral therapy in HIV-1 infected patients according to subtype B and non-B <i>G. Ciusa, A. Bonazza, G. Cuomo, M. Menozzi, F. Carli, G. Guaraldi, V. Borghi, C. Mussini</i>
69	P 31	Strongyloides stercoralis hyperinfection syndrome in a colombian HIV late presenter <i>A. Ricciardi<sup>1</sup>, G. Picchi<sup>1</sup>, A. Cellini<sup>1</sup>, N. Iapadre<sup>1</sup>, M. Mariani<sup>1</sup>, A. Ciccone<sup>2</sup>, F. Marinangeli<sup>2</sup>, G. Bruno<sup>3</sup>, A. Santini<sup>3</sup>, A. Grimaldi<sup>1</sup></i>
35	P 32	A nutraceutical combination targeting dyslipidemia and subclinical inflammation in HIV-infected patients on stable antiretroviral therapy <i>E. Schiaroli<sup>1</sup>, S. Cardaci<sup>1</sup>, V. Bianconi<sup>2</sup>, C. Papalini<sup>1</sup>, M. Pirro<sup>2</sup>, F. Baldelli<sup>1</sup>, D. Francisci<sup>1</sup></i>
216	P 33	Pneumocystosis as a complication of H1N1 Influenza A infection in an HIV positive patient under effective cART <i>I. Franconi<sup>1</sup>, C. Monari<sup>2</sup>, M. Tutone<sup>1</sup>, G. Ciusa<sup>1</sup>, L. Corradi<sup>1</sup>, E. Franceschini<sup>1</sup>, M. Meschiari<sup>1</sup>, C. Puzzolante<sup>1</sup>, G. Cuomo<sup>1</sup>, N. Riva<sup>1</sup>, A. Bianchi<sup>1</sup>, A. Raimondi<sup>1</sup>, W. Gennari<sup>3</sup>, M. Pecorari<sup>3</sup>, G. Guaraldi<sup>1</sup>, C. Mussini<sup>1</sup></i>
280	P 34	Cardiovascular risk in HIV-positive population: evaluation of the risk and serological markers <i>A. Auricchio, C. Ucciferri, F. Vignale, K. Falasca, J. Vecchiet</i>
74	P 35	Abnormal elevation of INR values in a patient during co-administration of E/C/F/TAF and warfarin: a case report <i>V. Malagnino, G. Maffongelli, C. Stingone, G. Malerba, E. Teti, M. Capozzi, L. Sarmati, M. Andreoni</i>

## Elenco Poster

ID	N. pgm	Title
----	--------	-------

218	P 36	Neurotoxoplasmosis in a sicilian HIV reference centre
-----	------	---

*A. Cervo, A. De Luca, B. Romanin, F. Scarlata*

296	P 37	Immune reconstitution inflammatory syndrome and Cytomegalovirus encephalitis: a case report
-----	------	---

*F. Trave, D.C. Cibelli, F. Sozio, A. Consorte, G. Parruti*

## HIV-associated and non HIV-associated cancers

17	P 38	Lenalidomide as maintenance therapy for refractory HIV-associated plasmablastic lymphoma: feasible and effective?
----	------	---

*I. De Benedetto<sup>1</sup>, L. Verga<sup>2</sup>, F.A. Brioschi<sup>2</sup>, D. Dalu<sup>3</sup>, C. Gambacorti Passerini<sup>2</sup>, A. Gori<sup>1</sup>, A. Bandera<sup>1</sup> for the Musthal Study Group*  
 \*Musthal Study Group: A. Bandera, L. Verga, I. De Benedetto, F. A. Brioschi, A. Gori, C. Gambacorti-Passerini, E. Doni, S. Bolis, G. Bozzi, E. Colella, M. Rossi, F. Pagni, B.E. Leone (San Gerardo Hospital, University of Milan Bicocca), Monza, F. Crippa, E. Suardi (San Paolo Hospital, University of Milan), D. Dalu, C. Fasola (Luigi Sacco Hospital Milan), M. Mena (Ospedale Civile of Legnano), O. Giglio, R. Epifani, D. Santoro (Sant'Anna Hospital Como), P. Vitiello, C. Zeroli, T. Quirino (Ospedale di Circolo of Busto Arsizio)

206	P 39	HCV-related hepatocellular carcinoma in people with or without HIV coinfection: a survival analysis of a single center cohort
-----	------	---

*A. Soria<sup>1</sup>, V. Castelli<sup>1</sup>, E. Colella<sup>1</sup>, N. Squillace<sup>1</sup>, M. Rossi<sup>1</sup>, A. Ciaccio<sup>2</sup>, A. Gori<sup>1</sup>, G.M. Migliorino<sup>1</sup>, G. Lapadula<sup>1</sup>*

90	P 40	Sepsis from MDR gram-negative bacteria a lethal complication in a group of HIV positive patients during chemotherapy for hematological malignancies
----	------	---

*C. Cerva<sup>1</sup>, L. Campogiani<sup>1</sup>, G. Maffongelli<sup>1</sup>, G. De Simone<sup>1</sup>, I. Provenzano<sup>2</sup>, D. Nasso<sup>2</sup>, M. Cantonetti<sup>2</sup>, W. Arcese<sup>2</sup>, M. Andreoni<sup>1</sup>, L. Sarmati<sup>1</sup>*

295	P 41	Oral plasmablastic lymphoma in HIV: a case report
-----	------	---

*F. Trave, D.C. Cibelli, F. Sozio, A. Consorte, G. Parruti*

285	P 42	Acute onset of fatal hematologic malignancy in HIV-1 infected patient: Report of a clinical case
-----	------	--

*G. Caruana<sup>1</sup>, S. Grignolo<sup>2</sup>, R. Prinapori<sup>2</sup>, V. Cassano<sup>2</sup>, A. Reali<sup>2</sup>, M. Guerra<sup>2</sup>, S. Artioli<sup>2</sup>*

## HIV-associated tuberculosis

92	P 43	Quantiferon-TB in HIV-positive patients: prognostic values and factors associated with indeterminate results
----	------	--

*V. Pirriatore<sup>1</sup>, F. Grosso<sup>1</sup>, V. Ghisetti<sup>2</sup>, S. Raviolo<sup>1</sup>, S. Faraoni<sup>2</sup>, I. Motta<sup>1</sup>, M. Milesi<sup>1</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>*

108	P 44	Rapid development of unmasking disseminated tuberculosis-related immune reconstitution inflammatory (TB-IRIS) syndrome in a HIV-infected patient after starting combination antiretroviral therapy
-----	------	--

*N. Ronzoni<sup>1</sup>, G. Borghero<sup>2</sup>, F. Porcu<sup>2</sup>, A. Sannia<sup>2</sup>, M. Ligas<sup>1</sup>, V. Fiore<sup>1</sup>, G. Madeddu<sup>1</sup>, S. Babudieri<sup>1</sup>*

227	P 45	The diagnostic challenge of central nervous system (CNS) lesions in the HIV-infected patient
-----	------	--

*M. Caixeiro<sup>1</sup>, F. Peruzzo<sup>2</sup>, R. Jesus<sup>1</sup>, B. Flor de Lima<sup>1</sup>, D. Trigo<sup>1</sup>, M.J. Lopes<sup>1</sup>, J. Batista<sup>1</sup>, P. Pacheco<sup>1</sup>*

## Coinfections/sexually transmitted infections

169	P 46	Predictive score of Neurosyphilis (NS) in HIV infected persons: when to perform a lumbar puncture?
-----	------	--

*L. Celani<sup>1</sup>, C. Borrazzo<sup>1</sup>, A. Lazzaro<sup>1,2</sup>, S. Giuliano<sup>3</sup>, S. Savinelli<sup>1</sup>, E.N. Cavallari<sup>1</sup>, G. Corano-Scheri<sup>1</sup>, C. Pinacchio<sup>1</sup>, A. Vullo<sup>4</sup>, G. Ceccarelli<sup>1</sup>, C.M. Mastroianni<sup>1</sup>, G. d'Ettore<sup>1</sup>*

203	P 47	Chemsex and risk of Sexually Transmitted Infections (STI): a pilot survey
-----	------	---

*M. Colafigli, F. Roscini, C. Ancona, S. Foracappa, A.E. Levi, M. Frasca, D. Orsini, L. Alei, M.G. Donà, M. Giuliani, A. Cristaudo, A. Latini*

275	P 48	Scaling up Hepatitis A vaccination through a community-based intervention among MSM population during 2016-2017 epidemic outbreak
-----	------	---

*S. Coladonato<sup>1</sup>, L. Badia<sup>1</sup>, V. Guardigni<sup>1</sup>, A. Gianninoni<sup>2</sup>, M.C. Risi<sup>2</sup>, P. Viale<sup>1</sup>, G. Verucchi<sup>1</sup>, S. Mattioli<sup>3</sup>*

40	P 49	The impact of multiple HPV-types on the clinical outcome of HPV infection
----	------	---

*L. Ronga<sup>2</sup>, G. Addati<sup>1</sup>, R. Magrone<sup>1</sup>, A. Abbasciano<sup>1</sup>, D. Di Carlo<sup>3,4</sup>, G. Miragliotta<sup>1,2</sup>, R. Del Prete<sup>1,2</sup>*

57	P 50	Cerebrospinal fluid/plasma biomarkers in patients with suspected neurosyphilis
----	------	--

*M. Scarvaglieri<sup>1</sup>, L. Di Girolamo<sup>2</sup>, S. Audagnotto<sup>2</sup>, A. Lucchini<sup>2</sup>, C. Costa<sup>2</sup>, L. Mighetto<sup>3</sup>, G. Di Perri<sup>2</sup>, I. Dal Conte<sup>1</sup>, A. Calcagno<sup>2</sup>*

221	P 51	An unusual case of hepatic syphilis mimicking a hepatocellular carcinoma
-----	------	--

*L. Bianchi, V. Bellelli, G. Russo, G. d'Ettore, C. D'Agostino, A. Ciardi, M.R. Ciardi, V. Vullo*

39	P 52	Improvement in quantitative detection of Human Herpesvirus 6 with a ready-to-use PCR-based Real Time PCR assay
----	------	--

*D. Rigamonti, M. Gramegna, M. Ballarini, M.L. Incandela, L.J. Turner, G. Ferri, L. Bavagnoli, L. Spinelli*

## Comorbidities HIV and HCV

## Elenco Poster

ID	N. pgm	Title
22	P 53	Prevalence of thyroid diseases in a cohort of HIV-infected people of Northern Italy <i>E. Quiros-Roldan, A. Ferraresi, T. Della Giustina, I. Izzo, M. Properzi, A. Bonito, A. Celotti, M.C. Pezzoli, R. Allegri, F. Castelnuovo, E. Focà, F. Castelli</i>
236	P 54	Longitudinal evaluation of neurocognitive performances in antiretroviral-treated HIV/HCV co-infected patients receiving Directly-Acting Antivirals <i>I. Mastroiosa, P. Lorenzini, C. Pinnetti, A.C. Brita, G. Fabbri, A. Vergori, M. Zaccarelli, A. Ammassari, A. Antinori</i>
58	P 55	Which factors delay the HCV treatment in patients with HIV/HCV co-infection? The HCV Cascade of Care among HIV+ patients at S. Maria Annunziata Hospital, Florence <i>F.M. Fusco<sup>1</sup>, E. Salomoni<sup>1</sup>, A. Poggi<sup>1</sup>, F. Vichi<sup>1</sup>, A. Degli Esposti<sup>1</sup>, P. Pierotti<sup>1</sup>, F. Baragli<sup>1</sup>, F. Esperti<sup>2</sup>, M. Di Pietro<sup>3</sup>, P. Blanc<sup>1</sup></i>
56	P 56	Markers of cumulative exposure to HIV viremia predict hepatocellular carcinoma occurrence in HIV patients treated with DAAs for Hepatitis C <i>V. Guardigni<sup>1,2</sup>, A. Casabianca<sup>1</sup>, S. Coladonato<sup>1</sup>, L. Badia<sup>1,2</sup>, P. Viale<sup>1</sup>, G. Verucchi<sup>1,2</sup></i>
84	P 57	Clinical experience with dolutegravir in HIV-HCV co-infected patients treated with Direct-acting Antivirals <i>S.T. Kirois<sup>1</sup>, F. Lagi<sup>1</sup>, I. Campolmi<sup>1</sup>, S. Giachè<sup>1</sup>, D. Bartolozzi<sup>2</sup>, A. Bartoloni<sup>1,2</sup>, G. Sterrantino<sup>2</sup></i>
191	P 58	Evaluation of transient detectable HIV-RNA (blips) in HIV/HCV coinfecting patients during therapy with direct acting antivirals: the experience of Infectious Disease Unit of Verona <i>D. Piacentini, S. Chiesi, S. Rizzardo, G. Carolo, E. Lattuada, E. Concia, E. Tacconelli, M. Lanzafame</i>
95	P 59	Impact of HCV eradication on lipidic, glyceimic and renal parameters in HIV+ co-infected patients <i>E. Milano<sup>1</sup>, C. Fabrizio<sup>1</sup>, L. Scudeller<sup>2</sup>, N. de Gennaro<sup>1</sup>, N. Ladisa<sup>1</sup>, L. Monno<sup>1</sup>, A. Saracino<sup>1</sup>, G. Angarano<sup>1</sup></i>
6	P 60	Significant improvement in liver steatosis after switching from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) <i>L. Calza, M. Borderi, V. Colangeli, S. Coladonato, B. Tazza, G. Fornaro, L. Badia, V. Guardigni, G. Verucchi, P. Viale</i>
290	P 61	HBV/HCV/HDV coinfection HIV positive patient: analysis of reciprocal viral dynamics in plasma, PBMC and liver tissue <i>G. Di Caprio, S. Martini, C. Monari, A. Cascone, N. Coppola</i>
63	P 62	Alexithymia in a group of HIV/HCV infected patients. Preliminary data <i>M. Vitale, A. Cappabianca, S. Madonia, N. Boffa</i>

## Clinical Hepatitis

14	P 63	Does baseline liver stiffness value influence fibrosis outcome after direct-acting antiviral treatment in HIV-HCV coinfecting patients? <i>G. Fornaro<sup>1</sup>, V. Guardigni<sup>1</sup>, F. Ravaioi<sup>2</sup>, L. Badia<sup>1</sup>, P.L. Viale<sup>1</sup>, D. Festi<sup>2</sup>, G. Verucchi<sup>1</sup></i>
237	P 64	Vitamin D deficiency and health-related quality of life in chronic Hepatitis C <i>D. Palazzo<sup>1</sup>, E. Biliotti<sup>1</sup>, R. Esvan<sup>1</sup>, F. Severini<sup>1</sup>, L. Volpicelli<sup>1</sup>, P. Perinelli<sup>1</sup>, P. Maida<sup>1</sup>, M. Spaziante<sup>1</sup>, L. Fontanelli Sulekova<sup>1</sup>, C. Franchi<sup>1</sup>, M. De Angelis<sup>1</sup>, G. Iaiani<sup>1</sup>, P. Rucci<sup>2</sup>, G. Taliani<sup>1</sup></i>
165	P 65	HCV and hepatic steatosis measured by Transient Elastography (CAP): the impact of HCV eradication in a population of patients treated with DAAs <i>E. Salomoni<sup>1</sup>, A. Degli Esposti<sup>1</sup>, A. Gabbuti<sup>1</sup>, P. Pierotti<sup>1</sup>, F. Vichi<sup>1</sup>, F. Baragli<sup>1</sup>, C. Blè<sup>1,2</sup>, F. Esperti<sup>1,2</sup>, L. Mecocci<sup>1</sup>, P. Blanc<sup>1</sup></i>
79	P 66	Immune Thrombocytopenic Purpura associated with Hepatitis A infection in a 39-year old man <i>G. Parrella, V. Iodice, N. Capoluongo, G. Di Flumeri, R. Viglietti, V. Sangiovanni, A. Chirianni</i>
205	P 67	Hepatitis B virus reactivation sustained by an HBsAg immune-escape mutant isolate in an anti-HBc positive patient in course of Sofosbuvir/Velpatasvir treatment of HCV infection: a case report <i>L. Foroghi<sup>1</sup>, V. Malagnino<sup>1</sup>, E. Teti<sup>1</sup>, M. Aragri<sup>2</sup>, C. Cerva<sup>1</sup>, M. De Masi<sup>1</sup>, A. Gentile<sup>1</sup>, R. Salpini<sup>2</sup>, V.C. Di Maio<sup>2</sup>, C. Sarrecchia<sup>1</sup>, M. Andreoni<sup>1</sup>, V. Svicher<sup>2</sup>, F. Ceccherini-Silberstein<sup>2</sup>, L. Sarmati<sup>1</sup></i>

## DAAs therapy in HCV

44	P 68	Viral dynamics in HCV infected patients with different genotypes during old and new direct-acting antiviral agents combination <i>S. Paolucci<sup>1</sup>, F. Novazzi, R. Gulminetti<sup>2</sup>, S. Novati<sup>2</sup>, R. Maserati<sup>2</sup>, G. Barbarini<sup>3</sup>, P. Sacchi<sup>3</sup>, A. Piralla<sup>1</sup>, F. Baldanti<sup>1,4</sup></i>
178	P 69	NS5A inhibitor natural resistance associated substitutions (RASs) in a cohort of genotype (GT) 1a and 1b Hepatitis C (HCV) chronically infected patients <i>P. Canepa<sup>1,2</sup>, L. Nicolini<sup>3</sup>, S. Marengo<sup>4</sup>, B. D'Ambrosio<sup>1,2</sup>, C. Arcuri<sup>1,2</sup>, G. Guarona<sup>1,2</sup>, G. Pieri<sup>4</sup>, A. Picciotto<sup>4</sup>, G. Icardi<sup>1,2</sup>, B. Bruzzone<sup>2</sup></i>

## Elenco Poster

ID	N. pgm	Title
172	P 70	Response to DAA among HIV-HCV co-infected people who inject drugs (PWID) in clinical practice <i>A. Tavelli<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, C. Mussini<sup>3</sup>, A. Castagna<sup>4</sup>, A. Saracino<sup>5</sup>, A. Cingolani<sup>6</sup>, B. Menzaghi<sup>7</sup>, G. Lapadula<sup>8</sup>, S. Savinelli<sup>9</sup>, A. Antinori<sup>10</sup>, A. d'Arminio<sup>11</sup>, M. Puoti<sup>12</sup> for Icona Foundation Study Group</i>
18	P 71	Changes in serum lipid profiles in the HIV-HCV co-infected patients treated with direct acting antivirals (DAAs) <i>M. Schiavini<sup>1</sup>, F. Niero<sup>1</sup>, A.L. Croci<sup>1</sup>, M. Passerini<sup>1</sup>, S. Landonio<sup>1</sup>, C. Magni<sup>1</sup>, V. Scalzi<sup>2</sup>, S. Vimercati<sup>2</sup>, L. Valsecchi<sup>1</sup>, M. Bolis<sup>1</sup>, S. Passerini<sup>1</sup>, N. Astuti<sup>1</sup>, P. Meraviglia<sup>1</sup>, G. Gubertini<sup>1</sup>, G. Rizzardini<sup>1</sup></i>
122	P 72	HCV patients and economic resources optimisation: the role of the DAA <i>E. Garagiola<sup>1</sup>, L. Ferrario<sup>1</sup>, B. Menzaghi<sup>2</sup>, A. Tebini<sup>2</sup>, G. Rizzardini<sup>3,4</sup>, M.V. Cossu<sup>3</sup>, E. Foglia<sup>1</sup>, D. Croce<sup>1,5</sup></i>
201	P 73	HIV-HCV coinfecting patients' fibrosis improves less after Direct-Acting Antiviral treatment: analysis of a single centre cohort <i>S. Oldrini<sup>1</sup>, D. Tomasoni<sup>1</sup>, V. Cappa<sup>2,3</sup>, S. Zaltron<sup>1</sup>, A. Spinetti<sup>1</sup>, P. Nasta<sup>1</sup>, C. Chirico<sup>1</sup>, C. Carriero<sup>1</sup>, G. Zuglian<sup>1</sup>, F. Castelnuovo<sup>1</sup>, L. Biasi<sup>1</sup>, E. Festa<sup>1</sup>, F. Castelli<sup>1</sup></i>
207	P 74	Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) during Direct-Acting Antiviral treatment. Is PLR a predictor of sustained virological response? <i>S. Odolini<sup>1</sup>, D. Tomasoni<sup>1</sup>, V. Cappa<sup>2,3</sup>, S. Zaltron<sup>1</sup>, A. Spinetti<sup>1</sup>, P. Nasta<sup>1</sup>, C. Chirico<sup>1</sup>, C. Carriero<sup>1</sup>, G. Zuglian<sup>1</sup>, F. Castelnuovo<sup>1</sup>, L. Biasi<sup>1</sup>, E. Festa<sup>1</sup>, F. Castelli<sup>1</sup></i>
29	P 75	Integrated efficacy and safety analysis of Italian population treated with Glecaprevir/Pibrentasvir in phase 3 clinical trials <i>A. Aghemo<sup>1</sup>, P. Andreone<sup>2</sup>, G. D'Offizi<sup>3</sup>, S. Fagioli<sup>4</sup>, M. Galli<sup>5</sup>, A. Gasbarrini<sup>6</sup>, P. Lampertico<sup>7</sup>, M. Persico<sup>8</sup>, M. Puoti<sup>9</sup>, G. Rizzardini<sup>10</sup>, G. Taliani<sup>11</sup>, E. Villa<sup>12</sup>, M. Vinci<sup>13</sup>, A.L. Zignego<sup>14</sup>, M. Zuin<sup>15</sup>, A. Perretti<sup>16</sup>, S. Petta<sup>17</sup></i>
11	P 76	Anti-HCV therapy in HIV/HCV co-infected patients <i>H. Ernandes<sup>1</sup>, L. Ammari<sup>1</sup>, R. Abdelmalek<sup>1</sup>, A. Berriche<sup>1</sup>, S. Aissa<sup>1</sup>, F. Kanoun<sup>1</sup>, H. Harrabi<sup>1</sup>, B. Kilani<sup>1</sup>, O. Bahr<sup>2</sup>, H.T. Benaissa<sup>1</sup></i>

## HCV eradication and model to access to care

233	P 77	Hepatitis C micro-elimination Project - ASL Roma 1 <i>P. Casella<sup>1</sup>, A. Torreggiani<sup>2</sup>, E. Dorigo<sup>2</sup>, A. Lupi<sup>1</sup>, S. Sereno<sup>3</sup>, T. Girolami<sup>1</sup>, E. Biliotti<sup>3</sup>, D. Palazzo<sup>3</sup>, A. Rugova<sup>3</sup>, M. Santori<sup>3</sup>, T. Petrangolini<sup>4</sup>, G. Taliani<sup>3</sup></i>
238	P 78	Clinical and virological characteristics of two paediatric patients on treatment with DAA <i>M. Mazzitelli<sup>1</sup>, N. Marascio<sup>2</sup>, G. Pavia<sup>2</sup>, C. Costa<sup>1</sup>, G. Giuseppe<sup>1</sup>, M.C. Postorino<sup>1</sup>, G.S. Barreca<sup>2</sup>, V. Pisani<sup>1</sup>, M.C. Liberto<sup>2</sup>, A. Focà<sup>2</sup>, C. Torti<sup>1</sup></i>
128	P 79	A model of care of HCV elimination in prison: an epidemiological Survey in the the remand Center of Padua <i>D. Lageder, V. Grigolin, L. Marcolongo, E. Conti, S. Lobello, F.A. Nava</i>
130	P 80	A model of Harm reduction program in an attenuate custody section for drug users: results and findings from the pilot experience of Padua prison <i>M. Rampazzo<sup>1</sup>, V. Minutella<sup>1</sup>, P. Vinti<sup>2</sup>, M. Galdiolo<sup>2</sup>, M. Costacurta<sup>2</sup>, G.B. Padovan<sup>1</sup>, F.A. Nava<sup>1</sup></i>

## Hepatitis Clinical diagnostics

255	P 81	Low performance of the OraQuick Hepatitis C Virus rapid antibody test in HIV/HCV infected individuals <i>S. Vita<sup>1</sup>, I. Pozzetto<sup>1</sup>, I. Mastrini<sup>1</sup>, R. Marocco<sup>1</sup>, L. Fondaco<sup>1</sup>, B. Kertusha<sup>1</sup>, V. Rossi<sup>1</sup>, T. Tieghi<sup>1</sup>, M. Lichtner<sup>1,2</sup> e C.M. Mastroianni<sup>2</sup></i>
24	P 82	HBV molecular epidemiology and clinical condition of immigrants living in Italy <i>C. Sagnelli<sup>1,2,3</sup>, M. Ciccozzi<sup>4</sup>, L. Alessio<sup>2</sup>, E. Cella<sup>4</sup>, L. Gualdieri<sup>5</sup>, M. Pisaturo<sup>2,6</sup>, C. Minichini<sup>1</sup>, G. Di Caprio<sup>2</sup>, M. Starace<sup>1</sup>, L. Onorato<sup>2</sup>, M. Capoprese<sup>2</sup>, L. Occhiello<sup>2</sup>, S. Angeletti<sup>4</sup>, G. Scotto<sup>7</sup>, M. Macera<sup>1,2</sup>, E. Sagnelli<sup>1</sup>, N. Coppola<sup>1</sup></i>
96	P 83	HCV genetic variability in patients with HCV-genotype 1-related hepatocellular carcinoma <i>M. Pisaturo<sup>1</sup>, C. Minichini<sup>1</sup>, M. Starace<sup>1</sup>, L. Occhiello<sup>1</sup>, A. Di Fraia<sup>1</sup>, N. Farella<sup>2</sup>, G. De Stefano<sup>2</sup>, V. Iodice<sup>2</sup>, N. Coppola<sup>1,3</sup></i>
193	P 84	HEV antibodies detection: comparison between two different commercially available assays <i>P. Caligiuri<sup>1,2</sup>, E. Furfaro<sup>1,3</sup>, L.A. Nicolini<sup>3</sup>, M. Mikulska<sup>3</sup>, G. Barisione<sup>1,2</sup>, R. Cerruti<sup>2</sup>, M. Ferraris<sup>2</sup>, G. Icardi<sup>1,2</sup>, B. Bruzzone<sup>2</sup></i>

## Hepatitis Epidemiology

183	P 85	Molecular epidemiology of HAV infection in Liguria: genetic analysis of HAV strains collected from December 2016 to February 2018 <i>P. Canepa<sup>1</sup>, B. D'Ambrosio<sup>1</sup>, C. Arcuri<sup>1</sup>, L. Santin<sup>2</sup>, C. Dentone<sup>3</sup>, M. Mela<sup>3</sup>, F. Briano<sup>4</sup>, A. Orsi<sup>1,2</sup>, F. Butera<sup>1</sup>, A. Schenone<sup>1</sup>, G. Icardi<sup>1,2</sup>, B. Bruzzone<sup>2</sup></i>
3	P 86	Epidemiology and risk factors for HCV infection among Italian intravenous drug users <i>A. Boschini<sup>1</sup>, M. Begnini<sup>1</sup>, R. Poletti<sup>1</sup>, C. Smacchia<sup>1</sup>, C. Sala<sup>2</sup>, G. Castellani<sup>2</sup>, M. Colombo<sup>3</sup></i>
4	P 87	Epidemiology and risk factors for HCV infection among Italian non-injection drug users <i>A. Boschini<sup>1</sup>, M. Begnini<sup>1</sup>, R. Poletti<sup>1</sup>, C. Smacchia<sup>1</sup>, C. Sala<sup>2</sup>, G. Castellani<sup>2</sup>, M. Colombo<sup>3</sup></i>

## Elenco Poster

ID	N. pgm	Title
----	--------	-------

## Hepatitis Pathogenesis

- |    |      |  |
|----|------|--|
| 37 | P 88 | Correlation between the hepatic concentrations of miR-125a-5p and the progression of liver damage in patients with overt and occult HBV infection<br><i>L. Onorato<sup>1</sup>, A. Russo<sup>2</sup>, G. de Stefano<sup>2</sup>, C. Minichini<sup>1</sup>, M. Panella<sup>3</sup>, V. Messina<sup>4</sup>, M. Starace<sup>1</sup>, P. Filippini<sup>4</sup>, N. Mosca<sup>3</sup>, L. Alessio<sup>4</sup>, L. Desiato<sup>3</sup>, N. Farella<sup>2</sup>, N. Potenza<sup>3</sup>, E. Sagnelli<sup>1</sup>, N. Coppola<sup>1</sup></i> |
|----|------|--|

## Hepatitis Treatment

- |     |      |  |
|-----|------|--|
| 246 | P 89 | Combination therapy with pegylated interferon and tenofovir in HBV/HDV-infected patients<br><i>A. Maccaro, L. Badia, V. Guardigni, P. Viale, G. Verucchi</i>   |
| 77  | P 90 | Off label retreatment of a patient failed to NS5A based DAAs regimen with advanced liver failure: a case report<br><i>E. Ciraci<sup>1</sup>, S. Semeraro<sup>1</sup>, G. Angarano<sup>2</sup>, L. Monno<sup>2</sup>, L. Lepore<sup>2</sup>, P. Gatti<sup>1</sup></i> |
| 212 | P 91 | Treatment with IFN-free regimen in a cohort of patients affected by chronic hepatitis C and psychiatric disorders: a retrospective analysis<br><i>T. Lupia, L. Bogliione, G. Cariti, S. Mornese Pinna, G. Di Perri</i>   |

## HIV Epidemiology

- |     |       |  |
|-----|-------|--|
| 99  | P 92  | HIV infection among transgender patients: our experience<br><i>C. Papalini, S. Cardaci, S. Bastianelli, S. Pierucci, C. Sfara, F. Baldelli, D. Francisci</i>   |
| 142 | P 93  | Acceptability of HIV rapid test: comparison of capillary whole blood test and oral fluid test in outpatient service for migrants in Italy<br><i>G. Chiaradia<sup>1</sup>, P. Scognamiglio<sup>1</sup>, P. Piselli<sup>1</sup>, C. Angeletti<sup>1</sup>, M. Oldrini<sup>2</sup>, E. Albertini<sup>3</sup>, A. Camposeragna<sup>4</sup>, M. Farinella<sup>5</sup>, D. Lorenzetti<sup>6</sup>, L. Rancilio<sup>7</sup>, G. Ippolito<sup>1</sup>, E. Girardi<sup>1</sup></i>  |
| 9   | P 94  | Significant spread to the native Italian population of HIV-1 non-B subtypes and worse virological response at week 48 to first-line cART: a single cohort experience in a region with a high migration rate<br><i>I. Izzo<sup>1</sup>, M.A. De Francesco<sup>2</sup>, F. Gargiulo<sup>2</sup>, E. Quiros-Roldan<sup>1</sup>, F. Invernici<sup>1</sup>, F. Castelnuovo<sup>1</sup>, E. Focà<sup>1</sup>, A. Bonito<sup>1</sup>, A. Caruso<sup>2</sup>, F. Castelli<sup>1</sup></i>  |
| 126 | P 95  | Low prevalence of HTLV1/2 infection in a population of sub-Saharan immigrants living in Southern Italy<br><i>L. Occhiello<sup>2</sup>, L. Alessio<sup>1,3,4</sup>, C. Minichini<sup>2</sup>, M. Starace<sup>2</sup>, M. Caroprese<sup>3,4</sup>, G. Di Caprio<sup>2,3,4</sup>, C. Sagnelli<sup>2,3,5</sup>, L. Gualdieri<sup>6</sup>, M. Pisaturo<sup>2,3,4</sup>, L. Onorato<sup>2,3,4</sup>, G. Scotto<sup>7</sup>, M. Macera<sup>2,3,4</sup>, S. De Pascalis<sup>2</sup>, E. Sagnelli<sup>2</sup>, N. Coppola<sup>1,2</sup></i> |
| 180 | P 96  | Prevalence of drug resistance and circulating viral subtypes in a real -life cohort of ART naïve HIV positive patients from 2005-2017<br><i>L. Mazzuti<sup>1</sup>, T. Melengu<sup>1</sup>, I. Mezzaroma<sup>2</sup>, G. d'Ettore<sup>3</sup>, E. Cella<sup>4</sup>, C. Fimiani<sup>3</sup>, G. Iaiani<sup>5</sup>, M. Falciano<sup>3</sup>, M. Ciccozzi<sup>4</sup>, G. Antonelli<sup>1</sup>, O. Turriziani<sup>1</sup></i>  |
| 283 | P 97  | Impact of tuberculosis and HIV infection on healthcare activities of infectious disease units in the Calabria region<br><i>M. Mazzitelli<sup>1</sup>, E. Raffetti<sup>2</sup>, L. Cosco<sup>3</sup>, R. Marino<sup>4</sup>, A. Mastroianni<sup>5</sup>, N. Serrao<sup>6</sup>, G. Apuzzo<sup>5</sup>, G. Berardelli<sup>7</sup>, J. Carioti<sup>6</sup>, D. Teti<sup>4</sup>, S. Nisticò<sup>7</sup>, L. Surace<sup>8</sup>, G. Foti<sup>9</sup>, C. Torti<sup>1</sup></i>   |
| 232 | P 98  | Late presentation and six months survival in a cohort of HIV+ subjects diagnosed across the last years in Catania<br><i>A. Pampaloni, M.E. Locatelli, A. Marino, D. Scuderi, M. Maresca, L. Vinci, R. Fontana del Vecchio, R. Bruno, M. Gussio, F. Palermo, B. Cacopardo, B.M. Celesia</i>   |
| 243 | P 99  | Therapy switch in an HIV-infected female cohort: the therapy adherence issue and the ADR risk<br><i>G. Piazza<sup>1</sup>, L. Appolloni<sup>1</sup>, S. Vitale<sup>1</sup>, I. Martens<sup>1</sup>, J. Baldi<sup>1</sup>, M. Morotti<sup>1</sup>, L. Calza<sup>2</sup>, C. Puggioli<sup>1</sup></i>  |
| 272 | P 100 | Molecular epidemiology of HIV-2 infected migrant in asylum seeker centre<br><i>E. Cella<sup>1</sup>, S. Vita<sup>2</sup>, G. Ceccarelli<sup>2</sup>, M. Fogolari<sup>3</sup>, V. Scolamacchia<sup>1</sup>, G. d'Ettore<sup>2</sup>, V. Vullo<sup>2</sup>, S. Angeletti<sup>3</sup>, M. Ciccozzi<sup>1</sup></i>  |
| 189 | P 101 | HIV-1 Subtypes and Circulating Recombinant Forms (CRFs) and blood donation NAT screening test: experience of LIGURIA Region<br><i>G. Ubezio<sup>1</sup>, A. Di Biagio<sup>2</sup>, M. Setti<sup>3</sup>, N. Nigro<sup>4</sup>, A. Marghero<sup>1</sup>, G. Barisione<sup>4,5</sup>, M.C. De Luigi<sup>1</sup>, P. Strada<sup>1</sup>, B. Bruzzone<sup>4</sup></i>  |
| 7   | P 102 | Foreign women under 49 years: a high risk group for HIV infection. A single center study in Brescia, Northern Italy<br><i>I. Izzo, A. Celotti, B. Sacconi, M. Properzi, E. Quiros-Roldan, A. Ferraresi, M.C. Pezzoli, R. Allegri, F. Castelnuovo, F. Castelli</i>  |
| 16  | P 103 | Direct distribution anti-HIV drugs through the Edotto system: appropriateness, traceability and innovation<br><i>F. Diguseppe, L. D'Aprile</i>   |
| 8   | P 104 | Epidemiological and clinical characteristics of newly diagnosed HIV infected patients: a single center study in Northern Italy<br><i>I. Izzo, M. Properzi, A. Celotti, B. Sacconi, E. Focà, E. Van Hauwermeiren, M.A. Forleo, I. El-Hamad, F. Castelnuovo, F. Castelli</i>   |

## Elenco Poster

ID N. pgm Title

### HIV cascade and retention in care

**109 P 105** Epidemiological and clinical characteristics of HIV-infected patients lost to follow up (LTFU) and re-engaged in care: a single-cohort observational study in Northern Italy

*A. Comelli, I. Izzo, E. Quiros-Roldan, F. Castelnuovo, G. Paraninfo, A. Ferraresi, F. Invernici, G. Zambolin, F. Castelli*

**36 P 106** Retention in care of HIV-positive patients from 2005 to 2014: comparison between Italian and non Italian patients

*C. Gabrielli, E. Schiaroli, G. De Socio, C. Papalini, M. B. Pasticci, F. Baldelli, D. Francisci*

### HIV Prevention

**10 P 107** Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis: a safe option

*A. Franco<sup>1</sup>, L. Aprea<sup>2</sup>, N. Papa<sup>3</sup>, T. Pizzella<sup>2</sup>, F. Simioli<sup>2</sup>, E. Manzillo<sup>2</sup>*

**34 P 108** Project Schools, "Anlaidis Lazio meets the students": an in/formative school prevention campaign on HIV/AIDS/STI, in cooperation with the National Institute for infectious diseases Spallanzani, to promote safe behaviors and a mindful sexuality in the Lazio Region.

*R. Galipò<sup>1</sup>, E. Farinola<sup>1</sup>, A. Ferraroni<sup>1</sup>, P. Ferri<sup>1</sup>, F. Maroso<sup>1</sup>, S. Ondedei<sup>1</sup>, N. Orchi<sup>2</sup>, A. Palummieri<sup>1</sup>, A. Pulimeno<sup>3</sup>*

**112 P 109** PrEP awareness and willingness in Italy, a one-month cross sectional study in a free access outpatient clinic

*A. Santoro, G. Guaraldi, G. Campagna, A. Bianchi, N. Riva, I. Franconi, A. Bonazza, A. Raimondi, C. Rogati, C. Ciusa, M. Tutone, C. Mussini*

**252 P 110** HIV seroconversion after stopping TDF-based treatment for HBV

*B. Tazza, L. Badia, V. Guardigni, G. Verucchi, P. Viale*

**179 P 111** Unconsistent use of condom in heterosexual HIV-serodiscordant couples from Southeastern Italy as revealed by the detection of Y chromosomal DNA in vaginal swabs

*F. Zoboli<sup>1</sup>, M. Di Stefano<sup>1</sup>, M. Fasano<sup>1</sup>, S.R. Bruno<sup>1</sup>, T.A. Santantonio<sup>1</sup>, J.R. Fiore<sup>1,2</sup>*

### HIV clinical diagnostics

**202 P 112** Going towards undetectable: preliminary results

*B. Bruzzone<sup>1</sup>, M. Setti<sup>2</sup>, A. Di Biagio<sup>3</sup>, R. Barresi<sup>1</sup>, N. Nigro<sup>1</sup>, A. Torretta<sup>4</sup>, G. Guarona<sup>1,5</sup>, P. Strada<sup>4</sup>, G. Ubezio<sup>4</sup>*

**208 P 113** Evaluation of the rapid HIV-1 RNA quantification Xpert HIV-1 Viral load assay: comparison with the COBAS AmpliPrep/COBAS TaqMan HIV test

*T. Allice, M.G. Milia, E. Burdino, G. Gregori, T. Ruggiero, M. Malta, E. Scuccimarra, P. Tremante, V. Ghisetti*

### HIV Immunology

**230 P 114** APOBEC3G/3A expression in HIV-1-infected individuals following initiation of antiretroviral therapy containing cenicriviroc or efavirenz

*D.A. Covino<sup>1</sup>, C. Purificato<sup>1</sup>, L. Catapano<sup>1</sup>, C.M. Galluzzo<sup>1</sup>, M.C. Gauzzi<sup>1</sup>, S. Vella<sup>1</sup>, E. Lefebvre<sup>2</sup>, M. Andreotti<sup>1</sup>, L. Fantuzzi<sup>1</sup>*

**184 P 115** Modulation of the Natural Killer Cell compartment during DAAs treatment in Interferon-naïve HCV patients: the impact of the type of DAA

*L.A. Nicolini<sup>1,2</sup>, S. Dettori<sup>1</sup>, F. Bozzano<sup>3,4</sup>, A. Di Biagio<sup>2</sup>, A. De Maria<sup>1,2,3,4</sup>*

**20 P 116** Peripheral loss of regulatory T cells and polyautoimmunity in a HIV-infected patient

*E. Quiros-Roldan, A. Ferraresi, M. Properzi, A. Bonito, A. Celotti, M.C. Pezzoli, R. Allegri, F. Castelnuovo, E. Focà, I. Izzo, F. Castelli*

**168 P 117** In HIV primary infection, early cART reduced gd T cell activation but failed to restore their polyfunctionality

*R. Casetti<sup>1</sup>, A. Sacchi<sup>1</sup>, V. Bordonì<sup>1</sup>, E. Cimini<sup>1</sup>, C. Pinnetti<sup>2</sup>, R. Libertone<sup>2</sup>, A. Ammassari<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>1</sup>*

**277 P 118** Evaluation of myeloid cells, classical, intermediate and non-classical monocytes, T-cell activation markers in virologically suppressed treated patients with DRV-based regimen

*S. Savinelli, S. Vita, C. Mascia, L. Celani, L. Bianchi, M. Lichtner, G. d'Ettoire, V. Vullo, C.M. Mastroianni*

**5 P 119** Association of inflammation and coagulation markers with clinical, virological or immunological progression of HIV-1 Infection in adult patients naïve to antiretroviral therapy and with a CD4+ T lymphocyte count above 500 cells/MCL

*L. Calza<sup>1</sup>, V. Colangeli<sup>1</sup>, M. Borderi<sup>1</sup>, R. Manfredi<sup>1</sup>, S. Coladonato<sup>1</sup>, B. Tazza<sup>1</sup>, I. Bon<sup>2</sup>, M.C. Re<sup>2</sup>, P. Viale<sup>1</sup>*

**198 P 120** HIV-1 and host restriction factors: relationship between viral reservoir and RFs expression levels

*V. D'Urbano<sup>1</sup>, S. Longo<sup>1</sup>, E. De Crignis<sup>1</sup>, A. Bertoldi<sup>1</sup>, G. Musumeci<sup>1</sup>, I. Bon<sup>1</sup>, L. Calza<sup>2</sup>, G. Gallinella<sup>3</sup>, M.C. Re<sup>1</sup>*

### Vaccines and immune-based therapies

**192 P 121** Vaccine usage extent in people living with HIV: a snapshot from a single center cohort

*N. de Gennaro, A. Procopio, C. Santoro, C. Fabrizio, D.F. Bavaro, N. Ladisa, S. Lo Caputo, L. Monno, A. Saracino, G. Angarano*

## Elenco Poster

ID N. pgm Title

## HIV Pathogenesis

**131 P 122** Impact of ART on dynamics of growth factors and cytokines in primary HIV infection  
V. Bordoni<sup>1</sup>, A. Sacchi<sup>1</sup>, R. Casetti<sup>1</sup>, E. Cimini<sup>1</sup>, C. Pinnetti<sup>2</sup>, A. Mondì<sup>2</sup>, A. Ammassari<sup>2</sup>, A. Antinori<sup>2</sup>, C. Agrati<sup>1</sup>

**38 P 123** MicroRNA profile and CD4/CD8 ratio recovery after antiretroviral therapy  
A. Gabrieli<sup>1</sup>, L. Dioni<sup>2</sup>, C. Favero<sup>2</sup>, M. Tarkowski<sup>1</sup>, E. Gervasi<sup>1</sup>, S. Limonta<sup>1</sup>, M. Galli<sup>1</sup>, V. Bollati<sup>2</sup>, A. Riva<sup>3</sup>

## HIV Virology

**186 P 124** No impact of minor accessory mutations to Integrase strand transfer inhibitors (INSTI) on cART effectiveness after 24 weeks of follow-up: a longitudinal single-cohort study  
A. Celotti<sup>1</sup>, M. Properzi<sup>1</sup>, M. De Francesco<sup>2</sup>, F. Gargiulo<sup>2</sup>, I. Izzo<sup>1</sup>, E. Quiros-Roldan<sup>1</sup>, F. Castelnuovo<sup>1</sup>, A. Bonito<sup>1</sup>, A. Ferraresi<sup>1</sup>, M.C. Pezzoli<sup>1</sup>, A. Caruso<sup>2</sup>, F. Castelli<sup>1</sup>, E. Focà<sup>1</sup>

**195 P 125** Epidemiological analysis of primary resistance to Integrase strand -transfer inhibitors in real life setting from January 2016 to December 2017 in "D. Cotugno" Hospital, Naples (Italy)  
S. Mascolo<sup>1</sup>, A. Raddi<sup>2</sup>, M. Sardo<sup>1</sup>, V. Sangiovanni<sup>1</sup>, L. Atripaldi<sup>2</sup>, N. Cuomo<sup>2</sup>

**51 P 126** NK cell-mediated lysis of CD4+ T lymphocytes harboring reactivated HIV-1  
M.G. Desimio, E. Giuliani, M. Doria

**123 P 127** Role of low-level viremia during chemotherapy for non-hodgkin lymphoma  
G. Bozzi<sup>1</sup>, I. De Benedetto<sup>1</sup>, L. Verga<sup>1</sup>, S. Malandrini<sup>1</sup>, V. Micheli<sup>2</sup>, M. Mena<sup>3</sup>, E. Doni<sup>1</sup>, D. Dalu<sup>2</sup>, C. Fasola<sup>2</sup>, E. Colella<sup>1</sup>, A. Muscatello<sup>1</sup>, C. Gambacorti-Passerini<sup>1</sup>, A. Gori<sup>1</sup>, A. Bandera<sup>1</sup> for the Musthal study group

**181 P 128** Apoptotic effects in macrophages infected by CXCR4- but not by CCR5-viruses, caused by the involvement of HIV-1 coreceptors  
A. Borrajo<sup>1,3</sup>, A. Ranazzi<sup>1</sup>, M.C. Bellocchi<sup>1</sup>, M. Pollicita<sup>1</sup>, V. Svicher<sup>1</sup>, C.F. Perno<sup>1</sup>, S. Aquaro<sup>1,2</sup>

## Neuropathogenesis and neurologic complications

**49 P 129** Mini-Addenbrooke's Cognitive Examination test for HIV-Associated Neurocognitive Disorders  
M. Trunfio<sup>1</sup>, M. Milesi<sup>1</sup>, D. Vai<sup>2</sup>, C. Montrucchio<sup>1</sup>, C. Alcantarini<sup>1</sup>, M.C. Tettoni<sup>1</sup>, G. Orofino<sup>3</sup>, S. Audagnotto<sup>1</sup>, D. Imperiale<sup>2</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>, A. Calcagno<sup>1</sup>

## Pediatric, adolescent, maternal, fetal aspects

**41 P 130** Viral and Immunological Profile of HIV-1 chronically infected children under cART with or without persistent suppression of HIV-1 plasmaviremia  
A. Dalzini<sup>1</sup>, G. Ballin<sup>1</sup>, F. Carmona<sup>2</sup>, R. Freguja<sup>1</sup>, M.R. Petrara<sup>1</sup>, M. Zanchetta<sup>2</sup>, O. Rampon<sup>3</sup>, C. Giaquinto<sup>3</sup>, A. de Rossi<sup>1,2</sup>

**228 P 131** Rilpivirine during pregnancy: is it associated with preterm delivery?  
F. Peruzzi<sup>1</sup>, M.J. Lopes<sup>2</sup>, M. Caixeiro<sup>2</sup>, D. Trigo<sup>2</sup>, J. Batista<sup>2</sup>, B.F. de Lima<sup>2</sup>, G. Madeddu<sup>1</sup>, S. Babudieri<sup>1</sup>, P. Pacheco<sup>2</sup>

**125 P 132** Adherence to antiretroviral therapy in HIV+ Adolescents: an open issue for multidisciplinary team  
G. Orofino<sup>1</sup>, M. Guastavigna<sup>1</sup>, M. Farenga<sup>1</sup>, D. Penoncelli<sup>1</sup>, S. Carosella<sup>1</sup>, S. Lupo<sup>2</sup>, G. Cinnirella<sup>3</sup>, C. Gabiano<sup>4</sup>, P. Caramello<sup>1</sup>

**143 P 133** Effects of universal access to ART on MTC transmission and maternal health in West Cameroon  
A.M. Doro Altan<sup>1</sup>, L. Palombi<sup>2</sup>, F. Ciccacci<sup>2</sup>, F. Taafo<sup>3</sup>, J. Castro Forns<sup>1</sup>, S. Orlando<sup>2</sup>, S. Mancinelli<sup>2</sup>, C. Marazzi<sup>4</sup>

## Pharmacology, pharmacogenomics and drug interactions

**47 P 134** How relevant are drug-drug interactions between boosted antiretroviral -based regimens and calcium channel blockers in real life?  
D. Cattaneo<sup>1,2</sup>, T. Formenti<sup>3</sup>, N. Astuti<sup>3</sup>, P. Meraviglia<sup>3</sup>, A. Ridolfo<sup>3</sup>, C. Gervasoni<sup>1,3</sup>

**19 P 135** A pharmacogenetic study in ritonavir treated patients: hematological and cardiovascular disease risk analysis  
J. Cusato, A. Calcagno, S. Allegra, M. Antonucci, L. Marinaro, A. De Nicolò, S. Bonora, G. Di Perri, A. D'Avolio

**66 P 136** Factors influencing sofosbuvir intracellular concentrations at one month of therapy  
J. Cusato, A. De Nicolò, L. Bogleione, G. Caviglia, M. Sciandra, S. Mornese Pinna, A. Ciancio, G. Troshina, A. Smedile, C. Carcieri, G. Cariti, G. Saracco, G. Di Perri, A. D'Avolio

**267 P 137** Use of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in a HIV-positive woman during pregnancy  
C. Alcantarini<sup>1</sup>, M. Tettoni<sup>1</sup>, L. Trentini<sup>1</sup>, C. Costa<sup>1</sup>, C. Montrucchio<sup>1</sup>, A. Trentalange<sup>1</sup>, N. Forni<sup>1</sup>, A. Barco<sup>1</sup>, G. Masuelli<sup>2</sup>, C. Scolfaro<sup>3</sup>, V. Avataneo<sup>1</sup>, A. De Nicolò<sup>1</sup>, A. D'Avolio<sup>1</sup>, A. Calcagno<sup>1</sup>, S. Bonora<sup>1</sup>, G. Di Perri<sup>1</sup>

**293 P 138** Myocardial infarction and other adverse drug reaction among antiretroviral treatment in HIV positive patients  
M. De Fina



## Elenco Poster

ID N. pgm Title

## Programmatic issues, implementation of diagnosis and care

- 171 P 139** Access to anti-HCV treatment with DAAs in the migrant population in Italy: data from the Piter cohort  
A. Saracino<sup>1</sup>, D.F. Bavaro<sup>1</sup>, S. Rosato<sup>2</sup>, A. Giorgini<sup>3</sup>, R. Corsini<sup>4</sup>, E. Castelli<sup>5</sup>, M. Vinci<sup>6</sup>, F. Baragli<sup>7</sup>, E. Biliotti<sup>8</sup>, A. Orlandini<sup>9</sup>, M. Monti<sup>10</sup>, A. Zanetto<sup>11</sup>, C. Baiguera<sup>6</sup>, G. Morsica<sup>12</sup>, A. Soria<sup>13</sup>, S. Bruno<sup>14</sup>, A. Ciancio<sup>15</sup>, V. Donati<sup>16</sup>, V. Calvaruso<sup>17</sup>, M.G. Quaranta<sup>2</sup> on behalf of PITER collaborating group
- 271 P 140** The motivation analysis of the HIV-infected patients to spontaneous access to the hospital psychotherapy service in San Raffaele Hospital  
M.M. Ratti, E. Sangiovanni, G.B. Delli Zotti, L. Sarno
- 204 P 141** Free to live well with HIV in prison  
A. Battistella<sup>1</sup>, S. Dell'Isola<sup>2</sup>, S. Babudieri<sup>3</sup>, G. Starnini<sup>4</sup>, M. Errico<sup>5</sup>, C. Frontini<sup>4</sup>, A. Borrelli<sup>5</sup>, F. Perocco<sup>1</sup>, M. Cascio<sup>5,6</sup>, M. Formisano<sup>5</sup>, *FLEW group\**  
\*Collaborators: E. Rastrelli, A. Ialungo, S. Marcellini, M. Scuderi, M. Merlino, S. Carbonara, L. D'Argenio, T. Prestileo, F. Di Lorenzo, E. Pontali, L. Butini, G. Korb
- 287 P 142** Doctor Apollo: a digital health tool to improve management and wellbeing of people living with HIV  
S. Vita<sup>1</sup>, R. Marocco<sup>1</sup>, I. Pozzetto<sup>1</sup>, G. Morlino<sup>2</sup>, E. Vigilante<sup>2</sup>, L. Fondaco<sup>1</sup>, B. Kertusha<sup>1</sup>, G. Colazingari<sup>1</sup>, V. Mercurio<sup>1</sup>, V. Vullo<sup>2</sup>, C.M. Mastroianni<sup>3</sup>, M. Lichtner<sup>1,3</sup>
- 65 P 143** Capillary free HIV testing at voluntary and counseling PEG Checkpoint: report of tests performed in 2016-2017  
S. Cardaci<sup>1</sup>, E. Albertini<sup>2</sup>, C. Sfara<sup>1</sup>, C. Papalini<sup>1</sup>, V. Scaglione<sup>1</sup>, E. Riguccini<sup>1</sup>, M. Nofri<sup>1</sup>, F. Paciosi<sup>1</sup>, A. Gidari<sup>1</sup>, C. Gabrielli<sup>1</sup>, G. Angeli<sup>1</sup>, D. Rosignoli<sup>1</sup>, P. Diana<sup>2</sup>, L. Ciaccarini<sup>2</sup>, M.G. Gaggini<sup>2</sup>, F. Baldelli<sup>1</sup>
- 291 P 144** BLQ Checkpoint: characteristics of users in the first 30 months of activity  
S. Mattioli, M. Bonanni, C. Degli Esposti, C. Franchini, P. Gorgoni, P. Pieralli, P. Tomasi, G.M. Corbelli
- 225 P 145** Financial costs related to antiretroviral treatment switch (Studio Costi attribuibili alla modifica di una terapia antiretrovirale-SCUDI). Preliminary analysis  
G. Cenderello<sup>1</sup>, B. Giannini<sup>2</sup>, M. Giacomini<sup>2</sup>, R. Ungaro<sup>3</sup>, N. Riccardi<sup>3</sup>, D. Fiorellino<sup>1</sup>, G. Cassola<sup>1</sup>, A. Di Biagio<sup>3</sup>
- 273 P 146** Psychological assessment of HIV-infected patients in need of a psychoterapeutic treatment: psychopathological related characteristics  
G.B. Delli Zotti, M.M. Ratti, E. Sangiovanni, L. Sarno

## Social and behavioural science, marginalized groups, community aspects and community surveys

- 117 P 147** Educational and training initiatives increase participants' competence about HIV  
L. Rancilio<sup>1,2</sup>, C. Neglia<sup>2</sup> and the AIDS network of Caritas Italiana
- 188 P 148** Alcohol use disorder in HIV infected people  
M. Scarzella<sup>1</sup>, G. Mozzone<sup>2</sup>, S. Rusconi<sup>3</sup>
- 15 P 149** Alice & frames - Alice e Cornici  
A. Infante
- 42 P 150** "What about AIDS?" Health education targeted at student population  
S. Antonelli, P. Roselli, P. Mancino, M.P. Sciotti, M.R. Ferrone, M. Marra, M. Grasso, S. Del Borrello, C. Di Giambattista
- 276 P 151** Should we improve student's knowledge about STIs? Preliminary results from a pilot project in a Secondary High School in Sassari, Italy  
N. Ronzoni, V. Fiore, P. Bagella, G. Caruana, F. Peruzzu, F. Mori Ubaldini, G. Flore, V. Nardi, A.G. Pintus, S. Babudieri, G. Madeddu
- 284 P 152** Testing MSM in cruising venues: perception of the risk of infection  
D. Zagato, A. Bianchi, A. Costantino, F.M. Esposito, G. Fissore, S. Lolli, M. Manfredini, V. Nicotera, D. Pennisi, A. Pezzotti, M. Pierini, F. Rossi, R. Rossotti, J. G. Scalisi, P. Testoni, P. Vinti, M. Zoia, M. Cernuschi
- 27 P 153** Serodiscordant partner: exception or normality?  
M. Zetti, A. Bianchi, M. Cernuschi
- 176 P 154** Behaviors and knowledge on HIV and sexually transmitted infections (STIs) among blood donors and people sensitive to donation  
V. Regine<sup>1</sup>, L. Pugliese<sup>1</sup>, A. Argenton<sup>2</sup>, V. Saturni<sup>2</sup>, F. Marchionni<sup>2</sup>, A. Simonetti<sup>2</sup>, B. Suligo<sup>1</sup>
- 262 P 155** The self-help group as a resource in better dealing with HIV infection: 10 years of experience in Arcobaleno AIDS  
S. Patrucco<sup>1</sup>, A. Siliato<sup>2</sup>, P. Gusmeroli<sup>3</sup>, P. Altini<sup>4</sup>, G. Orofino<sup>5</sup>
- 241 P 156** #SalutediGruppo: using the social network Facebook as virtual motivators to physical exercise and wellness for persons living with HIV  
F. Turrini<sup>1,2</sup>, M. Bonato<sup>3</sup>, L. Reiss<sup>4</sup>, L. Passeri<sup>1</sup>, L. Galli<sup>5</sup>, C. Vitobello<sup>1</sup>, A. Giordani<sup>1</sup>, S. Giuliani<sup>1</sup>, A. Meloni<sup>3</sup>, A. La Torre<sup>3</sup>, A. Lazzarin<sup>5</sup>, G. Merati<sup>3,6</sup>, P. Cinque<sup>1,4</sup>
- 116 P 157** A desk for a material assistance, psychological support and work orientation for HIV-positive - LABORES  
S. Negri<sup>1</sup>, M. Bagnato<sup>1</sup>, B. Bongini<sup>1</sup>, C. Falanga<sup>2</sup>

## Elenco Poster

ID	N. pgm	Title
----	--------	-------

### Translational sciences

**250 P 158** The role of HIV protease inhibitors on mesenchymal stem cells in vitro differentiation

*S. De Rose<sup>1</sup>, A. Cazzaniga<sup>2</sup>, V. Romeo<sup>2</sup>, J.A.M. Maier<sup>2</sup>, S. Rusconi<sup>1</sup>*

**129 P 159** Analyses of protective genetic polymorphisms in HIV-infected cART treated patients

*E.M. Lori<sup>1</sup>, A. Cozzi-Lepri<sup>2</sup>, M. Biasin<sup>1</sup>, V. Mercurio<sup>1</sup>, S. Lo Caputo<sup>3</sup>, F. Castelli<sup>4</sup>, A. Castagna<sup>5</sup>, A. Gori<sup>6</sup>, G. Marchetti<sup>7</sup>, C. Venditti<sup>8</sup>, M. Clerici<sup>9,10</sup>, A. d'Arminio Monforte<sup>7</sup>*

### Any other issue

**148 P 160** Prevalence, risk factors and subtypes of Blastocystis spp. in HIV infected patients in Italy

*L. Fontanelli Sulekova<sup>1</sup>, M. Maiorano<sup>1</sup>, S. Gabrielli<sup>2</sup>, G. Iaiani<sup>1</sup>, C. Fimiani<sup>1</sup>, M. De Angelis<sup>1</sup>, E. Biliotti<sup>1</sup>, R. Esvan<sup>1</sup>, D. Palazzo<sup>1</sup>, M. Spaziante<sup>1</sup>, M. Rivano Capparuccia<sup>1</sup>, G. Taliani<sup>1</sup>*

**268 P 161** Vaccination coverage in HIV positive adult patients in ASL 1 Imperia

*I. De Macina<sup>1</sup>, R. Furnari<sup>2</sup>, D. Zollo<sup>2</sup>, M. Duberti<sup>2</sup>, A. Riccio<sup>1</sup>, C. Dentone<sup>1</sup>, M. Mela<sup>2</sup>*